Skip Navigation

European Heart Journal 1985 6(3):253-260;
Copyright © 1985 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by WALEFFE, A.
Right arrow Articles by KULBERTUS, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WALEFFE, A.
Right arrow Articles by KULBERTUS, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1985 The European Society of Cardiology

Electrophysiologic effects, antiarrhythmic activity and pharmacokinetics of cibenzoline studied with programmed stimulation of the heart in patients with supraventricular reentrant tachycardias

A. WALEFFE*, A. DUFOUR{dagger}, M.-F. AYMARD{dagger} and H. KULBERTUS*

*Division of Cardiology, Institute of Medicine, University of Liège Medical School Liège, Belgium
{dagger}UPSA Laboratories Rueil-Malmaison, France

Received 29 June 1984; revised 9 November 1984; .

Abstract

Cibenzoline, an imidazoline derivative is a new antiarrhythmic agent. Its electrophysiologicaleffects and antiarrhythmic properties were studied with programmed electrical stimulation of the heart in 12 patients with recurrent episodes of reentrant supraventricular tachycardia; atrionodal (5 cases), circus movement tachycardia involving an accessory pathway (6 cases), intraatrial reentry (one case).

Cibenzoline was infused intravenously at a dose of 1 mg kg-1 to 1.75 mg kg–1 during sustained episodes of tachycardia and over 9 to 15 min.

Cibenzoline shortened the sinus cycle length, moderately increased the transnodal conduction time and markedly lengthened the HV interval. The refractory periods of the atrioventricular (A–V) node, the atrium and the ventricle did not change.

The effects of cibenzoline on accessory pathways used in the anterograde direction were measurable in 4 cases. Complete blockade of the bypass was seen in every case. In the retrograde direction the refractory period of the bypass could be evaluated; in 5 patients it lengthened systematically.

Infused intravenously during epidoses of tachycardia, the drug terminated the rhythm disorder in 9 out of 12 cases. Tachycardia could still be initiated in 8 patients after i.v. cibenzoline (2 out of 5 A-V nodal tachycardias, 6 out of 6 circus movement tachycardias).

The distribution of the drug followed a bicompartment pharmacokinetic model. The plasma levels at the end of infusion ranged from 1.34 to 3.19 µg ml–1.

Cibenzoline, primarily has class I antiarrhythmic properties and its well-understood pharmacokinetics should be of help in tailoring the treatment to the individual needs of the patient.

Key Words: Cibenzoline • supraventricular reentrant tachycardia • programmed stimulation of the heart • pharmacokinetics of antiarrhythmics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.